Study of influence of sacubitril/valsartan on plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels in patients with heart failure

Yan-Fen Li; Chun-Hong Chen; Zhan-Qi Wang; Fang Wang; Ya Li

首页> 中文期刊> 《海南医科大学学报（英文版）》 >Study of influence of sacubitril/valsartan on plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels in patients with heart failure

Study of influence of sacubitril/valsartan on plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels in patients with heart failure

开具论文收录证明 >>

期刊封面封底目录下载 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Objective:To study the influence of sacubitril/valsartan on plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels in patients with heart failure. Methods: To choose 42 cases of chronic heart failure in our hospital form August 2017 to December 2017 as the study group, and 42 cases of chronic heart failure form January 2017 to June 2017 as the control group. The patients in the control group were treated with 80 mg valsartan on the basis of general treatment, 1 times a day, and the patients in the study group were added with 50mg sacubitril/valsartan on the basis of general treatment, 2 times a day. To compare the plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels before and after treatment in the two groups.Results:Before treatment, there was no statistical difference between the levels of plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 in the two groups; (1) After treatment, the levels of plasma NE, AngⅡ, ALD in the control group compared with those before treatment in the seme group, there were significant differences, and there were significant differences between the two groups; (2) After treatment, the levels of serum sCD40L, sICAM-1, sFas, sFasL in the control group compared with those before treatment in the same group, there were significant differences, and there were significant differences between the two groups; (3) After treatment, the levels of serum cTnI, MMP-9 in the control group compared with those before treatment in the seme group, there were significant differences, and there were significant differences between the two groups.Conclusion: The application of sacubitril/valsartan to patients with heart failure on the basis of general treatment, not only could significantly improve the levels of plasma NE, AngⅡ, ALD, and also could significantly improve the levels of serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9, the curative effect was more significant, it was worthy for clinical research and application.

著录项

来源
《海南医科大学学报（英文版）》 |2018年第6期|9-12|共4页
作者
Yan-Fen Li; Chun-Hong Chen; Zhan-Qi Wang; Fang Wang; Ya Li;
展开▼
作者单位

Department of Medicine, Baoding Hengtian Hospital, Hebei Baoding 071000 China;

Department of Cardiology, Affiliated Hospital of Hebei University, Baoding 071000 China;

Department of Cardiology, Affiliated Hospital of Hebei University, Baoding 071000 China;

Department of Cardiology, Affiliated Hospital of Hebei University, Baoding 071000 China;

Department of Cardiology, Affiliated Hospital of Hebei University, Baoding 071000 China;

展开▼
原文格式 PDF
正文语种 eng
中图分类
关键词

Study of influence of sacubitril/valsartan on plasma NE, AngⅡ, ALD and serum sCD40L, sICAM-1, sFas, sFasL and cTnI, MMP-9 levels in patients with heart failure

摘要

著录项

相关主题

期刊订阅